| Literature DB >> 33143025 |
Guilin Chen1,2,3, Armel Jackson Seukep1,2,3,4, Mingquan Guo1,2,3.
Abstract
Marine drugs have long been used and exhibit unique advantages in clinical practices. Among the marine drugs that have been approved by the Food and Drug Administration (FDA), the protein-ligand interactions, such as cytarabine-DNA polymerase, vidarabine-adenylyl cyclase, and eribulin-tubulin complexes, are the important mechanisms of action for their efficacy. However, the complex and multi-targeted components in marine medicinal resources, their bio-active chemical basis, and mechanisms of action have posed huge challenges in the discovery and development of marine drugs so far, which need to be systematically investigated in-depth. Molecular docking could effectively predict the binding mode and binding energy of the protein-ligand complexes and has become a major method of computer-aided drug design (CADD), hence this powerful tool has been widely used in many aspects of the research on marine drugs. This review introduces the basic principles and software of the molecular docking and further summarizes the applications of this method in marine drug discovery and design, including the early virtual screening in the drug discovery stage, drug target discovery, potential mechanisms of action, and the prediction of drug metabolism. In addition, this review would also discuss and prospect the problems of molecular docking, in order to provide more theoretical basis for clinical practices and new marine drug research and development.Entities:
Keywords: marine drugs; mechanism of action; molecular docking; protein–ligand interaction; target protein
Mesh:
Substances:
Year: 2020 PMID: 33143025 PMCID: PMC7692358 DOI: 10.3390/md18110545
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of the 12 approved marine drugs of anticancer (a), antibacterial (b), analgesic (c), cardiovascular (d), and antiviral (e) agents [3,8]. BS: biological source. Abbreviations of amino acids: A, Alanine; C, Cysteine; D, Aspartic acid; G, Glycine; K, Lysine; L, Leucine; M, Methionine; R, Arginine; S, Serine; T, Threonine; Y, Tyrosine. FDA, Food and Drug Administration (USA); EMEA, European Medicines Evaluation Agency; AEMPS, Agencia Española de Medicamentos y Productos Sanitarios (Spain); HC, Health Canada; ISS, Istituto Superiore di Sanità (Italy); PMDA, Pharmaceuticals and Medical Devices Agency (Japan).
Figure 2The docking types of Lock–Key Model (a) and Induced Fit Theory (b).
Figure 3The interaction interfaces of the protein–ligand complexes. The ligand (red) represents the protein (a) or small molecule (b), respectively. The protein (receptor) is green.
Some representative molecular docking programs, and their algorithm characteristics and applications.
| Program Name | Algorithm Characteristics | Typical Applications | Ref. |
|---|---|---|---|
| DOCK | Step-by-step geometric matching strategy; AMBER force field experience-based scoring function. As a kind of commonly used molecular docking software, it can be used for docking between flexible small-molecule ligands and flexible proteins. | Protein–small molecule | [ |
| AutoDock | Lamarck genetic algorithm and experience-based scoring function; the flexibilities of small molecules and some residue side chains can be fully taken into consideration. | Protein–small molecule | [ |
| AutoDock Vina | The upgraded version of AutoDock; the success rate and calculation speed are greatly improved compared to AutoDock; simple parameter setting, easy to use, and parallel operation on multi-core machines for docking flexible ligands and flexible protein side chains. | Protein–small molecule | [ |
| MDock | Using the knowledge-based atomic–atomic contact potential scoring function, the flexibilities of proteins and small molecules are considered by using the conformations of the multiple proteins and small molecules during the docking process. | Protein–small molecule | [ |
| FlexX | The best conformation is selected according to the size of the docking free energy, which has the advantages of fast speed, high efficiency, and easy operation. It is the representative software of the flexible docking and can also be used for the virtual screening of small molecule database. | Protein–small molecule | [ |
| GOLD | Based on the GA docking program, the ligand is completely flexible, the receptor binding position is partially flexible; the automatic docking program can be used for virtual screening of the database. Its accuracy and reliability are highly evaluated in the molecular docking simulation. | Protein–small molecule | [ |
| Surflex-Dock | The Hammerhead scoring function is used; it combines a large number of conformations from the intact molecules through a crossover process to achieve flexible docking. | Protein–small molecule | [ |
| eHiTS | An accurate and fast molecular docking program, which can be used to study ligand and receptor interactions and perform high-throughput virtual screening. | Protein–small molecule | [ |
| EADock | Multi-objective evolutionary optimization algorithm for docking small molecules with the active sites of proteins. | Protein–small molecule | [ |
| Glide | Docking program based on search algorithms, including the modes of extra precision (XP), standard precision (SP), and a high-throughput virtual filter. It is mainly used for the flexible docking of small-molecule ligands and proteins. | Protein–small molecule | [ |
| PIPER | FFT search algorithm; the knowledge-based atomic statistical potential scoring function, and applied to the ClusProServer | Protein–protein | [ |
| ZDOCK | FFT search algorithm; filtering and sorting with RDOCK. | Protein–protein | [ |
| Hammerhead | Fragment-based docking program for automated and rapid molecular docking of flexible ligands; the program uses an experience-based adjustment scoring function and a method to automatically identify and describe protein binding sites for molecular docking. | Protein–protein/small molecule | [ |
| MOE | A comprehensive software system for the pharmaceutical and life science, which could fully support drug design and research through molecular simulation, protein structure analysis, small molecule database processing and protein and small-molecule docking research in a unified operating environment. | Protein–protein/small molecule | [ |
| FLIPDock | A genetic algorithm-based docking program that uses the FlexTree data structure to represent the protein–ligand complex and enables docking of flexible ligands and flexible proteins. | Protein–protein/small molecule | [ |
| ICM-Dock | User-friendly interactive image display, and the software also supports fast and accurate docking optimization. | Protein–protein/polypeptide/small molecule | [ |
| HADDOCK | Docking program based on experimental data (such as NMR chemical shifts and point mutations), which was invented from protein–protein docking and can also be used for protein–ligand docking. | Protein–protein/DNA/RNA/small molecule | [ |
| RosettaDock | MC search algorithm; the experience-based energy scoring function. | Protein–protein/DNA/RNA/small molecule | [ |
| DOT | FFT search algorithm; the scoring function only has Van der Waals and electrostatic terms. | Protein–protein/DNA/RNA | [ |
| FLOG | Rigid docking program using a pre-generated conformation database | Protein–protein/DNA/RNA | [ |
| MS-Dock | The method consists of two main steps: first, generate a variety of 3D conformations; second, carry out the rigid docking of the conformations and multi-step virtual screening. | Protein–protein/DNA/RNA | [ |
Abbreviations: Ref., Reference; FFT, fast Fourier transform; GA, genetic algorithm; MC, Monte Carlo; MOE, molecular operating environment; GOLD, genetic optimisation for ligand docking; eHiTS, electronic high-throughput screening; EADock, evolutionary algorithm for docking; FLIPDock, flexible ligand–protein docking; ICM-Dock, internal coordinate modeling docking; HADDOCK, high ambiguity driven biomolecular docking; ZDOCK, Zhiping Weng docking; DOT, daughter of TURNIP; FLOG, flexible ligands oriented on Grid; MS-Dock, multi-stage Dock.
Figure 4Structures of three halogenated compounds isolated from marine algae Symphyocladia latiuscula. Abbreviations: 2,3-DA, 2,3,6-tribromo-4,5-dihydroxybenzyl alcohol; 2,3-ME, 2,3,6-tribromo-4,5- dihydroxybenzyl methyl ether; bis-2,3-DE, bis-(2,3,6-tribromo-4,5-dihydroxybenzyl)ether.
Figure 5Potential compounds isolated from the seaweeds of Dictyopteris hoytii.
Figure 6Two sulfated sterol derivatives (solomonsterols A, B) isolated from Theonella swinhoei.
Figure 7Two polyether derivatives (compounds 1, 2) isolated from the thalli of Gracilaria salicornia.
Figure 8Chemical structures of metabolites 1–8 isolated from the soft coral Sarcophyton ehrenbergi.
Figure 9Structures of the small molecule compounds isolated from the marine sponge Xestospongia exigua (Araguspongine C) and the octocoral Plexaura homomalla (Prostaglandin A2 and Prostaglandin A2-AcMe), respectively.